Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Dreyling

Showing results (11-20 of 336) with videos related to

Pageof 34
Sort By:
Hematology. American Society of Hematology. Education Program|December 17, 2009
Current treatment standards and emerging strategies in mantle cell lymphomaMartin Dreyling, Wolfgang Hiddemann,
Hematology/Oncology Clinics of North America|October 29, 2008
Therapy of mantle cell lymphoma: current standards and future strategiesChristian Schmidt, Martin Dreyling
Nature Clinical Practice. Oncology|November 3, 2005
Does the combination of rituximab and thalidomide influence the long-term perspectives of advanced-stage MCL?Georg Lenz, Martin Dreyling
Current Hematologic Malignancy Reports|April 29, 2010
Rituximab maintenance therapy in follicular lymphomaRoswitha Forstpointner, Martin Dreyling
Blood|August 23, 2014
How to treat old MCL patients: one size fits it all?Martin Dreyling, Simone Ferrero,
Hematological Oncology|June 9, 2023
Mantle cell lymphoma-Update on molecular biology, prognostication and treatment approachesElisabeth Silkenstedt, Martin Dreyling
Current Opinion in Oncology|July 23, 2013
The current therapeutic scenario for relapsed mantle cell lymphomaSimone Ferrero, Martin Dreyling
Leukemia & Lymphoma|May 1, 2015
Bendamustine and the immune system: a wolf in sheep's clothing?Martin Dreyling, Marion Subklewe
Haematologica|June 3, 2015
Personalized medicine in lymphoma: is it worthwhile? The mantle cell lymphoma experienceMartin Dreyling, Simone Ferrero,
Current Opinion in Oncology|December 25, 2008
Dose-intense treatment of mantle cell lymphoma: can durable remission be achieved?Martin Dreyling, Wolfgang Hiddemann
Pageof 34

Showing results (11-20 of 336) with videos related to

Sort By:
Pageof 34
Hematology. American Society of Hematology. Education Program|December 17, 2009
Current treatment standards and emerging strategies in mantle cell lymphomaMartin Dreyling, Wolfgang Hiddemann,
Hematology/Oncology Clinics of North America|October 29, 2008
Therapy of mantle cell lymphoma: current standards and future strategiesChristian Schmidt, Martin Dreyling
Nature Clinical Practice. Oncology|November 3, 2005
Does the combination of rituximab and thalidomide influence the long-term perspectives of advanced-stage MCL?Georg Lenz, Martin Dreyling
Current Hematologic Malignancy Reports|April 29, 2010
Rituximab maintenance therapy in follicular lymphomaRoswitha Forstpointner, Martin Dreyling
Blood|August 23, 2014
How to treat old MCL patients: one size fits it all?Martin Dreyling, Simone Ferrero,
Hematological Oncology|June 9, 2023
Mantle cell lymphoma-Update on molecular biology, prognostication and treatment approachesElisabeth Silkenstedt, Martin Dreyling
Current Opinion in Oncology|July 23, 2013
The current therapeutic scenario for relapsed mantle cell lymphomaSimone Ferrero, Martin Dreyling
Leukemia & Lymphoma|May 1, 2015
Bendamustine and the immune system: a wolf in sheep's clothing?Martin Dreyling, Marion Subklewe
Haematologica|June 3, 2015
Personalized medicine in lymphoma: is it worthwhile? The mantle cell lymphoma experienceMartin Dreyling, Simone Ferrero,
Current Opinion in Oncology|December 25, 2008
Dose-intense treatment of mantle cell lymphoma: can durable remission be achieved?Martin Dreyling, Wolfgang Hiddemann
Pageof 34